CLINICAL_TRIALS
research
· 2025-06-12
Clinical Trial Update: Frontline Oral Arsenic Trioxide for APL [Phase 2]
Summary
A Phase 2 trial evaluating frontline oral arsenic trioxide for acute promyelocytic leukemia is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: The University of Hong Kong | Conditions: Acute Promyelocytic Leukemia | Phase 2 | Status: RECRUITING